Home Technology EU Accuses Temu of Failing to Stop Illegal Product Sales, Risks Second Fine
TechnologyBusinessWorld

EU Accuses Temu of Failing to Stop Illegal Product Sales, Risks Second Fine

Share
Share

The European Union has taken fresh action against Chinese e-commerce giant Temu, accusing the company of failing to do enough to prevent illegal products from being sold on its platform.

The European Commission announced preliminary charges on Tuesday, November 17, 2026, citing weak product compliance checks, ineffective content moderation and inadequate penalties for sellers violating platform rules.

Temu, owned by PDD Holdings, disagreed with the findings, saying it has made significant efforts to address illegal product risks and will respond to the Commission.

If the allegations are confirmed, the company could face a fine of up to 6% of its annual worldwide turnover.

The latest action follows a €200 million fine imposed on Temu in May 2026 for failing to properly assess the risks of illegal products on its marketplace.

The European Commission had accepted Temu’s corrective action plan in October, but concerns over its enforcement measures remain.

Temu will have an opportunity to defend itself before the Commission makes a final decision.

See also  Nigerian Man Extradited to US Over Alleged $100m Tax Fraud, Identity Theft
Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Digital Payment Use Rises Among Nigerians Despite Fraud Experiences, Report Reveals

The 2026 State of Inclusive Instant Payment Systems in Africa (SIIPS) report,...

Banking Sell-Off Drags NGX Down as Investors Lose N406 Billion

Investors in Nigeria's stock market lost N406.34 billion in market value on...

African Businesses Face Shutdowns, Liquidation and Licence Revocations in Third Quarter of 2026

Several businesses across Africa faced shutdowns, insolvency proceedings and regulatory action in...

New pancreatic cancer pill raises hope as tumours disappear in early trials

A new daily pill, daraxonrasib, has shown promising results in early clinical...